NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today its participation in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Biennial Meeting, taking place May 30-June 2, 2026, at the Hilton Cleveland Downtown. The company will present its recently 510(k)-cleared OneRF Trigeminal Nerve Ablation System, designed to treat chronic facial pain and lesion nerve tissue for functional neurosurgical procedures.
The OneRF Trigeminal Nerve Ablation System features a multi-contact RF probe that enables precise mapping and ablation in fewer cycles without repositioning, potentially reducing procedural time and improving patient comfort. The system uses the OneRF Generator and received FDA clearance under K251243. NeuroOne recently completed the limited market release of this system.
In addition, NeuroOne will share details on its SEEG-Drug Delivery System, currently under development for investigational studies in humans and research in laboratory animals. The device is designed to deliver drugs, record, stimulate, support multiple trajectories, and enable repeated dosing through a single implant. It is not yet approved or cleared by the FDA.
The company will present a scientific presentation titled "Integrating Drug Delivery Capabilities into a SEEG-Based Recording, Stimulation, and Ablation Platform Technology" on Sunday, May 31, 2026, during Parallel Session 3: Device Development: Bench to Bedside. Two posters will also be presented: "SEEG-Guided Radiofrequency Ablation with Real-Time Temperature Control: From Early Clinical Experience to the Development of a Post-Market Registry" and "New FDA-cleared Multi-Contact RF Probe for Trigeminal Neuralgia: Cadaveric Feasibility and Usability Evaluation."
NeuroOne also looks forward to multiple neurosurgeon presentations on their clinical experiences with both the OneRF Radiofrequency Ablation System (brain) and the OneRF Trigeminal Nerve Ablation System. The OneRF Radiofrequency Ablation System is indicated for creating radiofrequency lesions in nervous tissue for functional neurosurgical procedures (FDA Clearance: K231675).
NeuroOne Medical Technologies Corporation focuses on improving surgical care for patients with neurological disorders. The company markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System, and OneRF Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations, lower costs, and improve patient outcomes. The company is also researching drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
For more information, visit nmtc1.com.
